Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

ANTH

Anthera Pharmaceuticals (CE) (ANTH)

Anthera Pharmaceuticals Inc (CE)
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:USOTC:ANTH
FechaHoraFuenteTítuloSímboloCompañía
12/09/201814:21Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)USOTC:ANTHAnthera Pharmaceuticals Inc (CE)
30/07/201815:45Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(b) (15-12b)USOTC:ANTHAnthera Pharmaceuticals Inc (CE)
27/07/201805:02Edgar (US Regulatory)Notice of Effectiveness (effect)USOTC:ANTHAnthera Pharmaceuticals Inc (CE)
20/07/201815:28Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)USOTC:ANTHAnthera Pharmaceuticals Inc (CE)
20/07/201815:28Edgar (US Regulatory)Withdrawal of Registration Statement (rw)USOTC:ANTHAnthera Pharmaceuticals Inc (CE)
20/07/201815:28Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)USOTC:ANTHAnthera Pharmaceuticals Inc (CE)
17/07/201813:38Edgar (US Regulatory)(25)USOTC:ANTHAnthera Pharmaceuticals Inc (CE)
09/07/201816:08Edgar (US Regulatory)Current Report Filing (8-k)USOTC:ANTHAnthera Pharmaceuticals Inc (CE)
27/06/201807:00GlobeNewswire Inc.Anthera Pharmaceuticals Announces Withdrawal of its Nasdaq Hearing Request and Suspension of Trading of its Securities on the...USOTC:ANTHAnthera Pharmaceuticals Inc (CE)
15/05/201815:00Edgar (US Regulatory)Quarterly Report (10-q)USOTC:ANTHAnthera Pharmaceuticals Inc (CE)
12/03/201807:00GlobeNewswire Inc.Anthera Pharmaceuticals Reports Top Line Data from the RESULT Phase 3 Clinical Study of SollpuraUSOTC:ANTHAnthera Pharmaceuticals Inc (CE)
07/03/201807:30GlobeNewswire Inc.Anthera Pharmaceuticals to Present at the 30TH Annual ROTH ConferenceUSOTC:ANTHAnthera Pharmaceuticals Inc (CE)
06/03/201816:31Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)USOTC:ANTHAnthera Pharmaceuticals Inc (CE)
06/03/201813:45GlobeNewswire Inc.Anthera Pharmaceuticals Deemed Compliant with Nasdaq Listing CriteriaUSOTC:ANTHAnthera Pharmaceuticals Inc (CE)
05/03/201816:32Edgar (US Regulatory)Annual Report (10-k)USOTC:ANTHAnthera Pharmaceuticals Inc (CE)
05/03/201815:05GlobeNewswire Inc.Anthera Pharmaceuticals Provides Business Update and Reports 2017 Fourth Quarter and Fiscal Year Financial ResultsUSOTC:ANTHAnthera Pharmaceuticals Inc (CE)
22/02/201815:29Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)USOTC:ANTHAnthera Pharmaceuticals Inc (CE)
08/02/201807:30GlobeNewswire Inc.Anthera Pharmaceuticals to Participate in the BIO CEO & Investor Conference and SunTrust Robinson Humphrey’s 4th Annual Orp...USOTC:ANTHAnthera Pharmaceuticals Inc (CE)
05/02/201807:30GlobeNewswire Inc.Anthera Concludes Last Patient Visit in the Phase 3 RESULT Clinical Study of SollpuraUSOTC:ANTHAnthera Pharmaceuticals Inc (CE)
25/01/201815:30GlobeNewswire Inc.Anthera Receives Positive Nasdaq Listing DeterminationUSOTC:ANTHAnthera Pharmaceuticals Inc (CE)
22/01/201807:30GlobeNewswire Inc.Anthera Announces Positive Outcome of Second Interim Futility Analysis in the Phase 3 RESULT Clinical Study of Sollpura: Stud...USOTC:ANTHAnthera Pharmaceuticals Inc (CE)
18/01/201816:29Edgar (US Regulatory)Statement of Ownership (sc 13g)USOTC:ANTHAnthera Pharmaceuticals Inc (CE)
11/01/201814:07Edgar (US Regulatory)Amended Small Company Offering and Sale of Securities Without Registration (d/a)USOTC:ANTHAnthera Pharmaceuticals Inc (CE)
09/01/201816:15GlobeNewswire Inc.Anthera Pharmaceuticals Announces Second Closing of $15 Million Private Placement OfferingUSOTC:ANTHAnthera Pharmaceuticals Inc (CE)
09/01/201805:38Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)USOTC:ANTHAnthera Pharmaceuticals Inc (CE)
08/01/201807:30GlobeNewswire Inc.Anthera Pharmaceuticals Announces Results of Special Meeting of StockholdersUSOTC:ANTHAnthera Pharmaceuticals Inc (CE)
03/01/201807:30GlobeNewswire Inc.Anthera Pharmaceuticals Announces Appointment of Patrick Murphy as Senior Vice President, ManufacturingUSOTC:ANTHAnthera Pharmaceuticals Inc (CE)
11/12/201707:30GlobeNewswire Inc.Anthera Pharmaceuticals Announces Positive Outcome of Interim Futility Analysis in the Phase 3 RESULT Clinical Study of Sollp...USOTC:ANTHAnthera Pharmaceuticals Inc (CE)
04/12/201705:17Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)USOTC:ANTHAnthera Pharmaceuticals Inc (CE)
29/11/201715:07Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(4) (424b4)USOTC:ANTHAnthera Pharmaceuticals Inc (CE)
 Showing the most relevant articles for your search:USOTC:ANTH

Su Consulta Reciente

Delayed Upgrade Clock